Diagnostic Consulting Center 1 Sliven EOOD
- Address
- Bulevard Hristo Botev 2a, 8804 Sliven, Bulgaria
Diagnostic Consulting Center 1 Sliven EOOD
Diagnostic Consulting Center 1 Sliven EOOD is a specialized medical research facility dedicated to advancing clinical knowledge across multiple therapeutic areas. The center demonstrates particular expertise in conducting complex clinical trials for both chronic inflammatory conditions and metabolic disorders, serving as a vital site for evaluating innovative pharmaceutical interventions in biologic-experienced patient populations.
- Rheumatological and autoimmune disorders, including active psoriatic arthritis in biologic-experienced patients
- Metabolic and cardiovascular conditions, with focus on severe hypertriglyceridemia and lipid management therapies
- Respiratory diseases, encompassing severe eosinophilic asthma and moderate-to-severe chronic obstructive pulmonary disease
- Gastroenterological conditions and vaccine research, including erosive esophagitis due to GERD and influenza prevention
The center's research portfolio reflects a comprehensive approach to managing complex, chronic conditions that significantly impact patient quality of life. With experience evaluating novel biologics, antisense oligonucleotides, mRNA-based vaccines, and next-generation therapeutics, the facility contributes valuable data on both safety and efficacy outcomes. The center's capabilities extend from managing trials in difficult-to-treat populations, such as those with biologic-refractory disease, to conducting comparative effectiveness studies against standard-of-care treatments across diverse disease states.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 14 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Janssen Cilag International1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Areteia Therapeutics Inc.2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diagnostic Consulting Center 1 Sliven EOOD
lock Showing 1 of 10 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia (SHTG) | Ionis Pharmaceuticals Inc. | Phase III | Not Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexpramipexole Dihydrochloride Monohydrate | 2 | Unknown | 2023-04-25 | 2024-10-14 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.